Masahiro Ohara, Tetsuya Nagata, Rintaro Iwata Hara, Kie Yoshida-Tanaka, Nozomi Toide, Kazunori Takagi, . . . Takanori Yokota. (2024). DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs. Elsevier.
Chicago Style (17th ed.) CitationMasahiro Ohara, et al. DNA/RNA Heteroduplex Technology with Cationic Oligopeptide Reduces Class-related Adverse Effects of Nucleic Acid Drugs. Elsevier, 2024.
MLA (9th ed.) CitationMasahiro Ohara, et al. DNA/RNA Heteroduplex Technology with Cationic Oligopeptide Reduces Class-related Adverse Effects of Nucleic Acid Drugs. Elsevier, 2024.
Warning: These citations may not always be 100% accurate.